

TABLE 3—CDRH GUIDANCES AND COLLECTIONS—Continued

COVID-19 guidance title	CFR cite referenced in COVID-19 guidance	Another guidance referenced in COVID-19 guidance	OMB Control No(s).	New Collection covered by PHE PRA Waiver
	807, subparts A through D .... 807, subpart E ..... 820 ..... 830 and 801.20 .....	..... ..... ..... .....	0910-0625 0910-0120 0910-0073 0910-0720	
				Manufacturer voluntary reporting to FDA of viral transport media manufacturing capacity information.
				Manufacturer voluntary reporting to FDA of sterile phosphate buffered saline/saline manufacturing capacity information.
Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised November 2021) (document number 20010-R4).				
		Emergency Use Authorization of Medical Products and Related Authorities; Guidance for Industry and Other Stakeholders.	0910-0595	
		Administrative Procedures for Clinical Laboratory Improvement Amendments of 1988 Categorization.	0910-0607	
	803 .....	Medical Device Reporting .....	0910-0437	
				Confirmation to FDA that the developer of a diagnostic or serology test on FDA's notification lists and for which an Emergency Use Authorization (EUA) request was submitted, wants FDA to continue reviewing its EUA request.

**IV. Electronic Access**

Persons with access to the internet may obtain COVID-19-related guidances at:

- FDA web page entitled “COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders,” available at <https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders>;
- FDA web page entitled “Search for FDA Guidance Documents” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>; or
- <https://www.regulations.gov>.

Dated: January 14, 2022.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2022-01146 Filed 1-20-22; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2022-N-0049]

**Revocation of Five Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the

Authorizations) issued to Cellex Inc. for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test, BioMérieux SA for the SARS-COV-2 R-GENE, Siemens Healthcare Diagnostics Inc. for the Atellica IM SARS-CoV-2 IgG (COV2G), Siemens Healthcare Diagnostics Inc. for the ADVIA Centaur SARS-CoV-2 IgG (COV2G), and Cepheid for the Xpert Omni SARS-CoV-2. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.

**DATES:** The Authorization for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test is revoked as of December 10, 2021. The Authorizations for the SARS-COV-2 R-GENE, Atellica IM SARS-CoV-2 IgG (COV2G), and ADVIA Centaur SARS-CoV-2 IgG (COV2G) are revoked as of December 17, 2021. The Authorization for the Xpert Omni SARS-CoV-2 is revoked as of December 20, 2021.

**ADDRESSES:** Submit written requests for a single copy of the revocations to the Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4338, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request or include a Fax number to which the revocations may be sent. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the revocations.

**FOR FURTHER INFORMATION CONTACT:** Jennifer J. Ross, Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4332, Silver Spring, MD 20993-0002, 240-402-8155 (this is not a toll-free number).

#### **SUPPLEMENTARY INFORMATION:**

##### **I. Background**

Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5) allows FDA to strengthen the public health protections against biological, chemical, nuclear, and radiological agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations. On April 1, 2020, FDA issued an EUA to Cellex Inc. for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test, subject to the terms of the Authorization. Notice of the

issuance of this Authorization was published in the **Federal Register** on June 5, 2020 (85 FR 34638), as required by section 564(h)(1) of the FD&C Act. On May 6, 2020, FDA issued an EUA to BioMérieux SA for the SARS-COV-2 R-GENE, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on July 14, 2020 (85 FR 42407), as required by section 564(h)(1) of the FD&C Act. On July 31, 2020, FDA issued an EUA to Siemens Healthcare Diagnostics Inc. for the Atellica IM SARS-CoV-2 IgG (COV2G), subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on November 20, 2020 (85 FR 74346), as required by section 564(h)(1) of the FD&C Act. On July 31, 2020, FDA issued an EUA to Siemens Healthcare Diagnostics Inc. for the ADVIA Centaur SARS-CoV-2 IgG (COV2G), subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on November 20, 2020 (85 FR 74346), as required by section 564(h)(1) of the FD&C Act. On November 27, 2020, FDA issued an EUA to Cepheid for the Xpert Omni SARS-CoV-2, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on April 23, 2021 (86 FR 21749), as required by section 564(h)(1) of the FD&C Act. Subsequent updates to the Authorizations were made available on FDA's website. The authorization of a device for emergency use under section 564 of the FD&C Act may, pursuant to section 564(g)(2) of the FD&C Act, be revoked when the criteria under section 564(c) of the FD&C Act for issuance of such authorization are no longer met (section 564(g)(2)(B) of the FD&C Act), or other circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the FD&C Act).

##### **II. EUA Revocation Requests**

On December 7, 2021, Cellex requested withdrawal of, and on December 10, 2021, FDA revoked, the Authorization for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test. Because Cellex requested that FDA withdraw the Authorization and FDA understands the product is no longer being distributed, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization. On December 10, 2021, FDA received a request from BioMérieux SA for the revocation of, and on December 17, 2021, FDA revoked, the Authorization for the SARS-COV-2 R-GENE. Because

BioMérieux SA notified FDA that BioMérieux SA has decided to no longer commercially support the authorized product and requested FDA revoke the Authorization, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization. On December 9, 2021, FDA received a request from Siemens Healthcare Diagnostics Inc. for the voluntary removal of, and on December 17, 2021, FDA revoked, the Authorization for the Atellica IM SARS-CoV-2 IgG (COV2G). Because Siemens Healthcare Diagnostics Inc. notified FDA that Siemens Healthcare Diagnostics Inc. has decided to no longer market the authorized product and requested FDA voluntarily remove the Atellica IM SARS-CoV-2 IgG (COV2G) from FDA's list of authorized devices, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization. On December 9, 2021, FDA received a request from Siemens Healthcare Diagnostics Inc. for the voluntary removal of, and on December 17, 2021, FDA revoked, the Authorization for the ADVIA Centaur SARS-CoV-2 IgG (COV2G). Because Siemens Healthcare Diagnostics Inc. notified FDA that Siemens Healthcare Diagnostics Inc. has decided to no longer market the authorized product and requested FDA voluntarily remove the ADVIA Centaur SARS-CoV-2 IgG (COV2G) from FDA's list of authorized devices, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization. On December 17, 2021, FDA received a request from Cepheid for the revocation of, and on December 20, 2021, FDA revoked, the Authorization for the Xpert Omni SARS-CoV-2. Because Cepheid has notified FDA that Cepheid has not commercially distributed any of the Xpert Omni SARS-CoV-2 product due to the current public clinical needs being met by Cepheid's other EUA tests that are available and requested FDA revoke the EUA for the Xpert Omni SARS-CoV-2, FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization.

##### **III. Electronic Access**

An electronic version of this document and the full text of the revocations are available on the internet at <https://www.regulations.gov/>.

##### **IV. The Revocations**

Having concluded that the criteria for revocation of the Authorizations under section 564(g)(2)(C) of the FD&C Act are met, FDA has revoked the EUAs for

Cellex Inc.'s Cellex q-SARS-CoV-2 IgG/  
IgM Rapid Test, BioMérieux SA's  
SARS-CoV-2 R-GENE, Siemens  
Healthcare Diagnostics Inc.'s Atellica IM  
SARS-CoV-2 IgG (COV2G), Siemens

Healthcare Diagnostics Inc.'s ADVIA  
Centaur SARS-CoV-2 IgG (COV2G), and  
Cepheid's Xpert Omni SARS-CoV-2.  
The revocations in their entirety follow  
and provide an explanation of the

reasons for each revocation, as required  
by section 564(h)(1) of the FD&C Act.

BILLING CODE 4164-01-P



December 10, 2021

James X. Li, Ph.D.  
Chief Executive Officer  
Cellex Inc.  
76 TW Alexander Drive  
Research Triangle Park, NC 27709

**Re: Revocation of EUA200058**

Dear Dr. Li,

This letter is in response to Cellex Inc.'s (Cellex's) request dated December 7, 2021, that the U.S. Food and Drug Administration (FDA) withdraw the Emergency Use Authorization (EUA200058) for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test issued on April 1, 2020 and revised on June 12, 2020 and September 23, 2021. In its December 7 letter, Cellex requested withdrawal of the EUA effective December 10, 2021. FDA understands that the product is no longer being distributed.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Cellex requested that FDA withdraw the authorization and FDA understands the product is no longer being distributed, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA200058 for the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the Cellex q-SARS-CoV-2 IgG/IgM Rapid Test is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act

Sincerely,

*/s/*

\_\_\_\_\_  
Jacqueline A. O'Shaughnessy, Ph.D.  
Acting Chief Scientist  
Food and Drug Administration



December 17, 2021

Sophie Vernay  
Regulatory Affairs Manager  
BioMérieux SA  
376, Chemin de L'Orme  
Marcy L'Etoile, FR 69280  
**Re: Revocation of EUA200445**

Dear Ms. Vernay:

This letter is in response to BioMérieux SA's (BioMérieux's) request received December 10, 2021, that the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA200445) for the SARS-COV-2 R-GENE issued on May 6, 2020 and amended on November 6, 2020 and September 23, 2021. BioMérieux indicated that due to the current public clinical needs being met by other EUA assays that are available on the market, BioMérieux has decided to no longer commercially support the authorized product.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because BioMérieux has notified FDA that BioMérieux has decided to no longer commercially support the authorized product and requested FDA revoke the authorization, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA200445 for the SARS-COV-2 R-GENE, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the SARS-COV-2 R-GENE is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

Jacqueline A. O'Shaughnessy, Ph.D.  
Acting Chief Scientist  
Food and Drug Administration



December 17, 2021

Ayu Sucipto  
Regulatory Affairs Specialist  
Siemens Healthcare Diagnostics Inc.  
511 Benedict Ave.  
Tarrytown, NY 10591  
**Re: Revocation of EUA201696**

Dear Ayu Sucipto:

This letter is in response to a request from Siemens Healthcare Diagnostics Inc. (Siemens), received December 9, 2021, that the U. S. Food and Drug Administration (FDA) voluntarily remove the Atellica IM SARS-CoV-2 IgG (COV2G) -EUA201696 issued on July 31, 2020 and amended on September 23, 2021 from FDA's list of authorized devices. FDA understands that the authorized product is no longer being marketed.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Siemens has notified FDA that Siemens has decided to no longer market the authorized product and requested FDA voluntarily remove the Atellica IM SARS-CoV-2 IgG (COV2G) -EUA201696 from FDA's list of authorized devices, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA201696 for the Atellica IM SARS-CoV-2 IgG (COV2G), pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the Atellica IM SARS-CoV-2 IgG (COV2G) is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

Jacqueline A. O'Shaughnessy, Ph.D.  
Acting Chief Scientist  
Food and Drug Administration



December 17, 2021

Ayu Sucipto  
Regulatory Affairs Specialist  
Siemens Healthcare Diagnostics Inc.  
511 Benedict Ave.  
Tarrytown, NY 10591  
**Re: Revocation of EUA201697**

Dear Ayu Sucipto:

This letter is in response to a request from Siemens Healthcare Diagnostics Inc. (Siemens), received December 9, 2021, that the U.S. Food and Drug Administration (FDA) voluntarily remove the ADVIA Centaur SARS-CoV-2 IgG (COV2G) – EUA201697 issued on July 31, 2020 and amended on September 23, 2021, from FDA's list of authorized EUA devices. FDA understands that the authorized product is no longer being marketed.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Siemens has notified FDA that Siemens has decided to no longer market the authorized product and requested FDA voluntarily remove the ADVIA Centaur SARS-CoV-2 IgG (COV2G) – EUA 201697 from FDA's list of authorized EUA devices, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA201697 for the ADVIA Centaur SARS-CoV-2 IgG (COV2G), pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the ADVIA Centaur SARS-CoV-2 IgG (COV2G) is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

Jacqueline A. O'Shaughnessy, Ph.D.  
Acting Chief Scientist  
Food and Drug Administration



December 20, 2021

Mohamed Shariff  
Sr. Manager, Regulatory Affairs  
Cepheid  
904 Caribbean Drive  
Sunnyvale, CA 94089-1189  
**Re: Revocation of EUA202699**

Dear Mohamed Shariff:

This letter is in response to a request from Cepheid, received December 17, 2021, that the U.S. Food and Drug Administration (FDA) revoke the EUA202699 for the Xpert Omni SARS-CoV-2 test issued on November 27, 2020 and amended on December 23, 2020, April 20, 2021 and September 23, 2021. Cepheid indicated that due to the current public clinical needs being met by Cepheid's other EUA tests that are available, Cepheid has not commercially distributed any of the authorized product.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Cepheid has notified FDA that Cepheid has not commercially distributed any of the Xpert Omni SARS-CoV-2 product due to the current public clinical needs being met by Cepheid's other EUA tests that are available and requested FDA revoke the EUA202699 for the Xpert Omni SARS-CoV-2 test, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA202699 for the Xpert Omni SARS-CoV-2, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the Xpert Omni SARS-CoV-2 is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

Jacqueline A. O'Shaughnessy, Ph.D.  
Acting Chief Scientist  
Food and Drug Administration

Cc: Suzette Chance, Senior Director Regulatory Affairs, Cepheid

Dated: January 14, 2022.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2022-01139 Filed 1-20-22; 8:45 am]

BILLING CODE 4164-01-C

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

[OMB No. 0915-0298—Revision]

#### Agency Information Collection

#### Activities: Proposed Collection: Public Comment Request; Maternal and Child Health Bureau Performance Measures for Discretionary Grant Information System

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.

**DATES:** Comments on this ICR should be received no later than March 22, 2022.

**ADDRESSES:** Submit your comments to [paperwork@hrsa.gov](mailto:paperwork@hrsa.gov) or by mail to the HRSA Information Collection Clearance Officer, Room 14N136B, 5600 Fishers Lane, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email [paperwork@hrsa.gov](mailto:paperwork@hrsa.gov) or call Samantha Miller, the acting HRSA Information Collection Clearance Officer at (301) 443-9094.

**SUPPLEMENTARY INFORMATION:** When submitting comments or requesting information, please include the information collection request title for reference.

*Information Collection Request Title:* Maternal and Child Health Bureau (MCHB) Performance Measures for

Discretionary Grant Information System (DGIS), OMB No. 0915-0298—Revision.

**Abstract:** Approval from OMB is sought to implement minor revisions to the MCHB Performance Measures for DGIS. Most of these measures are specific to certain types of programs and are not required of all grantees. The measures are categorized by domain (Adolescent Health, Capacity Building, Child Health, Children with Special Health Care Needs, Lifecourse/Crosscutting, Maternal/Women Health, and Perinatal/Infant Health), in addition to some program-specific measures. Grant programs are assigned domains based on their activities and individual grantees respond to only a limited number of performance measures that are relevant to their specific program.

**Need and Proposed Use of the Information:** The performance data collected through the DGIS serves several purposes, including grantee monitoring, program planning, performance reporting, and the ability to demonstrate alignment between MCHB discretionary programs and the Title V MCH Services Block Grant program. HRSA is making the following changes to the current OMB package for MCHB DGIS to more closely align data collection forms with current program activities:

**Removing the following existing forms:** Core 1 (Grant Impact), Capacity Building 2 (Technical Assistance), Capacity Building 7 (Direct Annual Access to Maternal and Child Health (MCH) Data), Training Form 13 (Diverse Adolescent Involvement (LEAH-specific)), Financial Form 2 (Project Funding Profile), and Financial Form 4 (Project Budget and Expenditures);

**Adding the following new form:** Training Form 14 (Teleconsultation and Training for Mental and Behavioral Health) and Leadership, Education, and Advancement in Undergraduate Pathways Training Program Trainee Information Form;

**Revising the following existing forms:** F2F (Family to Family Form 1), Financial Form 1 (MCHB Project Budget Details), Financial Form 4 (new name: MCH Discretionary Grant Project Abstract), and MCH Training Program Data Forms;

**Revising and Renumbering the following forms:** Core 3 (Health Equity) will become the new Core 1 (Health Equity), Financial Form 3 (Budget Details by Types of Individuals Served)

will become the new Financial Form 2 (Budget Details by Types of Individuals Served), Financial Form 5 (Number of Individuals Served (Unduplicated)) will become the new Financial Form 3 (Number of Individuals Served (Unduplicated)), and Financial Form 6 (Project Abstract) will become the new Financial Form 4 (Project Abstract); and

**Renumbering the following forms:** Core 2 (Quality Improvement) will become the new Capacity Building 4 (Quality Improvement), Capacity Building 3 (Impact Measurement) will become the new Capacity Building 2 (Impact Measurement), Capacity Building 4 (Sustainability) will become the new Capacity Building 3 (Sustainability), and Training 14 (Medium-Term Trainees Skill and Knowledge (PPC-Specific)) will become the new Training 13 (Medium-Term Trainees Skill and Knowledge (PPC-Specific)).

Non-substantive revisions also include updates to terminology, goals, benchmark data sources, and significance sections included in the measures' detail sheets. A performance measure detail sheet defines and describes each performance measure. Forms and detail sheets showing the proposed revisions are available upon request.

This revision will facilitate more efficient and accurate reporting of information related to capacity building activities, financial and demographic data, and training activities.

**Likely Respondents:** The grantees for MCHB Discretionary Grant Programs.

**Burden Statement:** Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.